To participate in this class action lawsuit, click here.
You can also call Brian Lundin, Esq., of Lundin Law PC, at 888-713-1033, or e-mail him at brian@lundinlawpc.com.
No class has been certified in the above action yet. Until a class is certified, you are not considered to be represented by an attorney. You may also choose to do nothing and be an absent class member.
According to the Complaint, the Registration Statement and Prospectus filed for Avinger's IPO contained materially false and misleading statements and/or failed to disclose: that the Company did not have adequate sales and marketing personnel to increase sales of its lumivascular platform products and to commercialize Pantheris; that Avinger already experienced problems with the robustness of its lumivascular platform devices, including Pantheris; that physicians and hospitals were requiring more extensive and comprehensive training and education on the benefits of Avinger's products to convince them to adopt and implement its lumivascular platform products instead of competing products and procedures available in the market; that the Company would not be able to achieve a rapid ramp rate for increased sales of its lumivascular platform; and that as a result of the above, Avinger was experiencing lower sales and revenues. Following this news, the Company's shares fell in value, causing investors harm according to the Complaint.
Lundin Law PC was founded by Brian Lundin, a securities litigator based in Los Angeles dedicated to upholding the rights of shareholders.
This press release may be considered Attorney Advertising in certain jurisdictions under the applicable law and rules of ethics.
Contact:
Lundin Law PC
Brian Lundin, Esq.
Telephone: 888-713-1033
Facsimile: 888-713-1125
brian@lundinlawpc.com
http://lundinlawpc.com/
SOURCE: Lundin Law PC
ReleaseID: 474046